Nike (NKE) PT Raised to $140 at Nomura Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
UBS Raises Price Target on Nike (NKE) to $137 Following 1Q16
September 25, 2015 10:23 AM EDTUBS reiterated a Buy rating on Nike (NYSE: NKE), and raised the price target to $137.00 (from $128.00), following the company's 1Q16 earnings results.
Analyst Michael Binetti commented, "Nike's global futures accelerated significantly to +17% ex-FX from +13% in F4Qvs our above-Consensus +14% est (Street was at... More
Canaccord Genuity Raises Price Target on Nike (NKE) to $119 Following 15c EPS Beat
September 25, 2015 10:12 AM EDTCanaccord Genuity reiterated a Hold rating on Nike (NYSE: NKE), and raised the price target to $119.00 (from $109.00), following the company's 1Q16 earnings results. NKE reported EPS of $1.34 vs. $1.19 consensus estimate.
Analyst Camilo Lyon commented, "NKE reported stellar FQ1 EPS of $1.34 vs. our $1.19 consensus... More
Pre-Open Stock Movers 09/25: (BLPH) (SIEN) (NKE) Higher; (INAP) (FINL) (PIR) Lower (more...)
September 25, 2015 9:29 AM EDT
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 50% HIGHER; announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's... More
Nike's (NKE) Price Target Raised to $140 at Deutsche Bank
September 25, 2015 8:48 AM EDTDeutsche Bank maintained a Buy rating on Nike (NYSE: NKE) and raised its price target to $140.00 (from $125.00). The change follows strong Q1 results. Analyst Dave Weiner noted its brand momentum is showing no signs of slowing.
"Nike put up yet another quarter of... More
Sterne Agee CRT Upgrades Nike (NKE) to Buy Following 1Q16 EPS Beat
September 25, 2015 8:28 AM EDTSterne Agee CRT upgraded Nike (NYSE: NKE) from Neutral to Buy with a price target of $150.00 following the company's 1Q16 results. EPS came in at $1.34 versus consensus estimate of $1.19.
Analyst Sam Poser commented, "Nike executes its mission of bringing "inspiration and... More
Piper Jaffray Raises Price target on Nike (NKE) Following 15c EPS BEat
September 25, 2015 7:35 AM EDTPiper Jaffray reiterated an Overweight rating on Nike (NYSE: NKE), and raised the price target to $130.00 (from $120.00), following the company's 1Q16 earnings results. EPS of $1.34 was well ahead of the Street's $1.19 estimate.
Analyst Erinn Murphy commented, "We are reiterating our Overweight rating and... More
FBR Capital Raises Price Target on Nike (NKE) to $120 Following 1Q16 EPS Beat
September 25, 2015 6:55 AM EDTFBR Capital reiterated a Market Perform rating on Nike (NYSE: NKE), and raised the price target to $120.00 (from $109.00) following the company's 1Q16 earnings report. NKE reported a solid EPS beat of $1.34 versus consensus of $1.19.
Analyst Susan Anderson commented, "NKE reported a solid F1Q16 EPS beat of $1.34 versus FBR/consensus of $1.18/... More
Nike (NKE) PT Raised to $136 at Jefferies
September 25, 2015 6:53 AM EDTJefferies analyst Edward Plank reiterated a Buy rating and bumped his price target on Nike (NYSE: NKE) to $136.00 (from $128.00) following strong Q1 results.
Plank commented, "Nike exceeded expectations on nearly all fronts in F1Q, even in China and Europe, where market fears were... More
Cowen Raises Price Target on Nike (NKE) to $140 Following 1Q EPS Growth
September 25, 2015 6:51 AM EDTCowen reiterated an Outperform rating on Nike (NYSE: NKE), and raised the price target to $140.00 (from $130.00), following the company's 1Q16 results. NKE reported EPS of $1.34, above consensus of $1.19. Nike reported constant currency futures growth of +17%, the strongest futures growth since Q3:12.
Analyst John Kernan... More
Sterne Agee CRT Upgrades Nike (NKE) to Buy
September 25, 2015 6:50 AM EDTSterne Agee CRT upgraded Nike (NYSE: NKE) from Neutral to Buy with a price target of $150.00.
For an analyst ratings summary and ratings history on Nike click here. For more ratings news on Nike click here.
Shares of Nike closed at $114.79 yesterday.
... MoreNike (NKE) Tops Q1 EPS by 15c; Futures Orders up 17%, ex. FX
September 24, 2015 4:16 PM EDTNike (NYSE: NKE) reported Q1 EPS of $1.34, $0.15 better than the analyst estimate of $1.19. Revenue for the quarter came in at $8.4 billion versus the consensus estimate of $8.22 billion.
Fiscal 2016 is off to a great start, said Mark Parker, President and CEO of NIKE, Inc.... More

